• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following list of names for the drugs described are "under consideration" by the USAN Council:

June 2016

gallium ga 68 dotate tumor imaging agent
lutetium lu 177 dotate treatment of cancer

May 2016

ajulemic acid treatment of cystic fibrosis
bocomarsen treatment of hematologic malignancies
empluzumab treatment of cancer
flaxalizumab treatment of hematologic cancers
momorsen treatment of hematologic malignancies
relaplumab treatment of cancer
rivogenleucel-l graft vs. host disease; genetically modified allogeneic cellular therapy
setigentucel-l treatment of pancreatic cancer
spirociclib reduction of chemotherapy-induced myelosuppression
trilaciclib reduction of chemotherapy-induced myelosuppression
vispetinib treatment of cancer

April 2016

eberlixizumab treatment of allergic asthma
finradenoson treatment of cancer
namidenoson treatment of cancer
netodenoson treatment of cancer
temivirsen treatment of hepatitis C